1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
2. Yasui K, Hashimoto E, Tokushige K, et al. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res. 2012;42:767–73.
3. Kaji K, Yoshiji H, Kitade M, et al. Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med. 2008;22:801–8.
4. Kato J, Koda M, Kishina M, et al. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med. 2012;30:107–13.
5. Kawai D, Takaki A, Nakatsuka A, et al. Hydrogen-rich water prevents progression of non-alcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology. 2012;56:912–21.